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physical function measured on the Activity of Daily Living (ADL)
subscale in the HOOS/KOOS questionnaires for hip and knee patients,
respectively. The primary end-point was 3 months after surgery. The
main secondary outcome was HOOS/KOOS Pain subscale.
Results: 165 patients randomised to the two groups were on average
67(SD8) years, 84 (51%) hadhipOAand92 (56%)werewomen.153 (93%)
underwent planned surgery and were evaluated postoperatively. There
was no statistically signiﬁcant difference in treatment effects between hip
or knee patients (p ¼ 0.7370). Three months postoperatively (primary
endpoint), no difference was found between groups for physical function
(4.4, 95% CI -0.8 to 9.5) or pain (4.5, 95% CI -0.8 to 9.9). However, therewas
a statistically signiﬁcant difference indicating an effect of exercise seen
over the entireperiod (baseline to3monthspostoperatively) (p¼0.0029).
Conclusion: Eight weeks of supervised neuromuscular exercise prior to
total joint arthroplasty (TJA) of the hip or knee did not confer additional
beneﬁts compared with TJA alone at 3 months after surgery. However,
the intervention group experienced a statistically signiﬁcant short-term
beneﬁt in physical function and pain, suggesting an earlier onset of
postoperative recovery.
Trial registration: ClinicalTrials NCT01003756.Large variability was seen in Harris Hip Scores and gait changes after total hip arthroplasty
Preoperative Mean(SD) Postoperative Mean (SD) Mean Change (SD) Change Range
Harris Hip Score 56.80 (13.94) 91.4 (10.9) 34.6 (16.1) -10 to +65
Speed (m/s) 1.02 (0.24) 1.19 (0.19) 0.17 (0.2) -0.36 to +0.82
Dynamic Hip Range of Motion (deg) 15.5 (6.0) 25.4 (6.2) 8.9 (5.8) -14.4 to +23.0
Peak Flexion Moment (%BWxHt) 4.29 (1.60) 5.95 (2.02) 1.66 (1.89) -5.08 to +7.01
Peak Extension Moment (%BWxHt) 1.78 (0.79) 2.74 (1.07) 0.96 (1.03) -1.40 to +5.08
Peak Adduction Moment (%BWxHt) 3.42 (1.07) 3.46 (0.96) 0.03 (1.15) -2.68 to +3.64
Peak Abduction Moment (%BWxHt) 1.64 (0.84) 1.91 (0.85) 0.27 (0.81) -1.82 to +2.35
Peak Internal Rotation Moment (%BWxHt) 0.37 (0.21) 0.50 (0.20) 0.12 (0.19) -0.35 to +0.63
Peak External Rotation Moment (%BWxHt) 0.33 (0.21) 0.42 (0.23) 0.09 (0.21) -0.41 to 0.68 -0.41 to 0.6854
AGE, GENDER, AND BODY MASS INDEX DO NOT EXPLAIN
INDIVIDUAL VARIABILITY IN CLINICAL AND GAIT RECOVERY AFTER
TOTAL HIP ARTHROPLASTY
O.A. Behery, K.C. Foucher. Rush Univ. Med. Ctr., Chicago, IL, USA
Purpose: After undergoing total hip arthroplasty (THA) for hip osteo-
arthritis, many patients have residual pain and functional deﬁcits and
persistent biomechanical deﬁcits measured using quantitative gait
analysis. Age, gender and body mass index (BMI) have been linked to
variability in clinical outcomes, with results differing by study. The
effect of these factors on the improvement in gait has never been
studied. The purpose of this study was to determine whether age,
gender, or BMI are related to change in clinical scores and gait variables
after THA.
Methods: We identiﬁed 125 subjects from an IRB-approved data
repository who were evaluated before and primary unilateral THA: age
61  10 y (range 27-85); 63 M /62 F; BMI 28.2  5.0 kg/m2 (range
18.5-47.4); follow-up time 159 mos (range 6-37). Gait analysis was
conducted using standard published methods. Variables analyzed
were speed, dynamic hip range of motion and 3D peak external
moments normalized to body weight and height (%BWxHt), averaged
from 2-4 trials collected at subjects’ self-selected normal walking
speed. The clinical outcome tool used was the Harris hip score (HHS),
which includes pain, function and activity domains and is scored from
0-100 (best). We used Pearson correlations to assess relationships
between age, BMI and gender and the change in HHS and gait vari-
ables. We also grouped subjects by age (<65, 65), gender (M / F), and
BMI (<25, 25-29.9, 30) and used t-tests and ANOVA to determine
whether pre-to-post change in HHS and gait variables differed
between groups.
Results: Substantial variation was seen in HHS and gait changes
(Table 1). On average, all variables signiﬁcantly increased (p<0.001)except for the peak adduction moment (p¼0.759). Individual change in
this moment, which reﬂects net hip abductor activity, ranged from
a decrease of 55% to an increase of 220% (Figure 1). There were no
signiﬁcant age or BMI correlations or group differences (p¼ 0.100-
0.972). Regarding gender, the hip adduction moment tended to increase
postoperatively in women (+0.231.3 %BWxHt) and decrease in men
(-0.161.0 %BWxHt) but this differences was not quite statistically
signiﬁcant (p¼ 0.055). Given the overlapping ranges of values, the lack
of differences in the other moments that reﬂect hip abductor function
(e.g. the internal and external rotation moments) and the number of
comparisons performed, this difference is not likely clinically mean-
ingful. No other gender comparisons approached signiﬁcance (p¼0.105-
0.988).
Conclusions: Considerable variability was present in both clinical and
gait changes after THA. The amount of variability in the pre-to-post
change in the peak adduction moment, which reﬂects hip abductor
function, was particularly noteworthy. Age, gender and BMI were not
related to HHS or gait changes. These ﬁndings suggest that THA can
provide signiﬁcant improvement for patients regardless of age, gender
or BMI, but more work is needed to identify factors related poor clinical
or biomechanical responses.Figure 1. Histograms showing the pre-to post-operative changes in peak adduction
moment and Harris Hip Score in our subject sample illustrate substantial individual
variation in improvement of clinical and gait outcomes after total hip arthroplasty.
Notably, the Harris Hip Score decreased for 4 (3%) subjects, while the peak adduction
moment declined for 61 (49%) subjects.
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IN HUMAN CHONDROCYTES DNMT-1 PLAYS A KEY ROLE IN THE
EXPRESSION OF SEVERAL GENES ASSOCIATED WITH THE
PATHOGENESIS OF OSTEOARTHRITIS (OA)
N. Akhtar, T.M. Haqqi. NEOMED Univ., Dept. Anatomy & Neurobiology,
Rootstown, OH, USA
Introduction: Recent evidence points to chromatin remodeling as a key
event in the expression of several genes associated with OA patho-
genesis. IL-1b is the principal cytokine involved in cartilage catabolism
in OA. The aim of this study was to investigate (a) whether IL-1b
modulates DNA methylation content in human chondrocytes; and if so
(b) how the DNA methylation status affect the expression of selected
Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62S36downstream genes; and (c) whether the effect on DNA methylation is
the same or different in chondrocytes from the 3 deﬁned histological
zones of the human articular cartilage.
Methods: Femoral head cartilage samples (n¼12) obtained at the time
of hip arthroplasty were stained with India ink and only the unaffected,
smooth cartilage was used. A portion of the cartilage was ﬁxed, decal-
ciﬁed and analyzed histologically. Chondrocytes were derived by
enzymatic digestion of superﬁcial zone (SZ), transition zone (TZ) and
deep zone (DZ) of the cartilage and cultured in monolayer. Chon-
drocytes stimulated with IL-1b (10ng/ml) in vitro for 24h were used in
these studies. Gene expression of 84 human epigenetic modiﬁcation
enzymes was studied using Human Epigenetic Chromatin Modiﬁcation
Enzymes RT2 Proﬁler PCR Array. Expression levels of DNMT-1, -3A,-
3B, Thymine DNA glycosylase (TDG) and of selected genes was quan-
tiﬁed by TaqMan Assays. Expression of Global DNA methylation level
was determined using MethylFlashTM Methylated DNA quantiﬁcation
kit. IL-1b-induced changes in the activity of DNMTs and DNA deme-
thylases was studied using commercially available kits. Effect of DNA
demethylation by a pharmacological agent 5-Aza-2 deoxycytidine (5-
Aza) on the expression of matrix metalloproteinases (MMPs), tissue
inhibitors of MMPs (TIMPs), cyclooxygenase-2 (COX-2) and SOX-9 was
also studied. SiRNA-mediated knockdown of DNMT-1 expression was
used to study its role in the regulation of selected genes. Results were
derived using Origin 6.1 software package and p<0.05 was considered
signiﬁcant.
Results: In IL-1b-stimulated chondrocytes, global DNA methylation
showed signiﬁcant increase in the DZ chondrocytes (128%) and in SZ
chondrocytes (44%), but not in TZ chondrocytes. Expression analysis of
84 genes whose products are known or predicted to modify genomic
DNA and histones to regulate gene expression, identiﬁed 30 genes that
displayed signiﬁcant differences in expression upon IL-1b-stimulation.
Results of both the mRNA array and TaqMan assays showed a signiﬁcant
up-regulation of DNMT-1, -3A and -3B gene expression upon IL-1b-
stimulation which correlated with the increased total DNMT and
DNMT-1 enzyme activity in both the SZ and DZ chondrocytes but not in
TZ chondrocytes. Interestingly, expression and activity of DNA deme-
thylases and TDG enzymes was also increased in SZ chondrocytes by IL-
1b-stimulation. Pharmacological DNA demethylation and knockdown
of DNMT-1 resulted in signiﬁcant increase in the expression of MMP-3,
MMP-9, MMP-13, TIMP-2, and COX-2 and transcription factor SOX-9 in
SZ chondrocytes.
Conclusions:We identify for the ﬁrst time several new candidate genes
that show epigenetic regulation in response to IL-1b in human chon-
drocytes. We also show that IL-1b induce hypermethylation of genomic
DNA in SZ and DZ chondrocytes, but not in TZ chondrocytes, which
positively correlated with the expression and activity of DNA methyl-
atranferases. IL-1b stimulation also increased the expression and
activity of DNA demethylases suggesting a dynamic regulation of DNA
methylation and demethylation in SZ chondrocytes. Our results also
suggest a role of DNMT1 activity in mediating epigenetic modiﬁcations
that regulate the expression of MMP-3, -9, -13, TIMP-2, SOX-9 and COX-
2 in human chondrocytes.56
OXIDATIVE STRESS INDUCED CHONDROCYTES APOPTOSIS WERE
INHIBITED BY EICOSAPENTAENOIC ACID
S. Sakata, S. Hayashi, T. Fujishiro, N. Kanzaki, S. Hashimoto, K.
Kawakita, K. Iwasa, N. Chinzei, R. Kuroda, M. Kurosaka. Kobe Univ.
Graduate School of Medicine, Kobe, Japan
Purpose: Osteoarthritis (OA) is the most common joint disease of
elderly population, and characterized by the progressive destruction
and loss of the articular cartilagematrix due to unbalanced anabolic and
catabolic activities of the chondrocytes. Apoptosis of chondrocytes has
been reported to be correlated with the severity of OA and is involved in
the progression of the disease. Nitric Oxide (NO) is a free radical that
undergoes a variety of reactions in tissues with other radicals, such as
superoxide. In OA cartilage, NO is present at higher level, and may play
an important role in the progression of OA. Overproduction of NO has
been reported to induce apoptosis of chondrocytes. Eicosapentaenoic
acid (EPA) is an antioxidant, and one of n-3 polyunsaturated fatty acid
which can be taken from ﬁsh oil. In molecular level, EPA reduces the
production of inﬂammatory cytokines such as IL-1 beta or TNF-a.
However, the mechanism of reduction in chondrocytes apoptosis stillhas been unknown. In this study, we investigated that oxidative stress-
induced chondrocytes apoptosis was regulated by EPA treatment.
Methods: Normal Human Chondrocytes were pretreated with 30 mg/ml
EPA for 8 hrs. After the treatment of EPA, 1mM Sodium nitroprusside
(SNP) which was used as an exogenous source of NOwas added, and the
cultures were incubated for further 12 hrs.
The expression of phosphorylated p38MAPK, phosphorylated p53,
cleaved PARP and cleaved caspases 3 were detected bywestern blotting.
Chondrocytes apoptosis was detected by Flow cytometry.
Results: We evaluated the effects of EPA on phosphorylation of
p38MAPK and p53 in response to oxidative stress. Western blotting
demonstrated that phosphorylation of p38MAPK and p53 were
increased by the treatment with SNP. However, exogenous EPA treat-
ment inhibited the phosphorylation of p38MAPK and p53 (Figure 1).
Further, we evaluated the effects of EPA on chondrocytes apoptosis in
response to oxidative stress. Flow cytometry showed that apoptosis in
chondrocytes were increased by SNP treatment, but chondrocytes
apoptosis were inhibited by the treatment with EPA (Figure 2). Western
blotting conﬁrmed that cleaved caspases 3 and PARP were increased by
the treatment with SNP, but decreased by the treatment with EPA
(Figure 3).
Conclusions: Our results demonstrated that EPA reduced the phos-
phorylation of p38MAPK and p53, and inhibited oxidative stress-
induced chondrocytes apoptosis. We can suggest that anti-apoptotic
function of EPA may work on p38-p53 pathway.Figure 1. The expression level of phosphorylated p38MAPK and p53 (Western
Blotting).Figure 2. The rate of chondrocytes apoptosis.Ă
